Gsk Plc · LSE:GSK
Gsk — Investor Day (May 2015)
10 slides from Gsk's investor day presentation, May 6, 2015
Slide 1: Group overview and strategic outlook
Sir Andrew Witty Group overview and strategic outlook 6 May 2015
Slide 2: Healthcare environment requires global, diversified and innovative offering
Healthcare environment requires global, diversified and innovative offering Growing population… Global footprint >6 billion >7 billion people people outside US & Europe Broad portfolio offering Driven by significant new cohorts… Regulatory and 650m quality ~1 billion 60+ new year olds competence bab
Slide 3: Long term strategic actions mean GSK is well positioned for new operating environment
Long term strategic actions mean GSK is well positioned for new operating environment Diversified business* Diversified geographies* Cost saving programmes £bn Cx 25% US Major 30% Change Rx, 1.0 Int 1.0 41% Rx Vx 59% 16% EU NVS, 29% 1.0 Offering value for money health interventions to prevent and tr
Slide 4: Capital allocation strategy to support growth and returns
Capital allocation strategy to support growth and returns Intention to retain full holding in ViiV Investment Accelerate restructuring of Group Provide new flexibility for possible generic Flexibility Advair and ViiV/Consumer put options 3 year ordinary dividend of 80p 2015-2017 Shareholder return £
Slide 5: GSK targeting improvements to financial performance
GSK targeting improvements to financial performance 2016-2020 Vx sales Group sales Mid-to-high single digit* Cx Expect low-to-mid single digit 25% CAGR for the Group* 12 month 2014 pro Rx sales Rx Vx forma** 59% Low single digit* Core EPS 16% 2016 expected to reach double digit CER growth Cx sales 2
Slide 6: Key success factors
Key success factors Vx Rx Cx Accelerate growth with Expand coverage in USA New launches strengthened portfolio Improve reach in emerging markets Established products ex US/EU Geographic footprint expansion Expand margins Deliver pipeline Expand margins R&D Commercial model >£6bn sales from 11 new pr
Slide 7: Broader and diversified portfolio offers sustained revenue protection
Broader and diversified portfolio offers sustained revenue protection Rx legacy Rx legacy devices*, devices*, 17% 17% Cx & Vx, 24% Other 2007 Rx***, 19% 2015 Q1 Cx & Vx, sales sales 42% Other Rx***, Rx outside US/EU/Japan, 42% 15% Rx 10(+) year Rx outside patent** US/EU/Japan, 5% 17% Rx 10(+) year p
Slide 8: The GSK proposition
The GSK proposition Volume driven Significant R&D High level exposure to capability to drive pipeline opportunities broad healthcare growth with reduced and low concentration markets and global reliance on price of patent risk, post GDP growth Advair/Seretide Leadership positions in Consumer & Expec
Slide 9: Cautionary statement regarding forward-looking statements
Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements. Forward-looking statements give the Group’s current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly t
Slide 10: Unaudited pro forma financial information
Unaudited pro forma financial information The unaudited pro forma financial information in this presentation has been prepared to illustrate the effect of (i) the disposal of the oncology assets, (ii) the Consumer Healthcare joint venture (i.e. the acquisition of the Novartis OTC Business), and (iii